Rhino-Orbital Cerebral Mucormycosis (ROCM): Effective Management with Liposomal Amphotericin B

Published on: September 2025 Indian Journal of Pharmacy Practice, 2026; 19(1):123-126. Case Report| doi: 10.5530/ijopp.20260258Authors and affiliation (s): Dhanush R1,*, Yogeesha BS2, Ganesh P Surahonne2 1Department of Pharmacy Practice, Bapuji Pharmacy College, Davangere, Karnataka, INDIA. 2Department of Otorhinolaryngology, SSIMS&RC, Davangere, Karnataka, INDIA. ABSTRACT Rhino-Orbital Cerebral Mucormycosis (ROCM) is a serious and often life-threatening fungal infection. The fungi class called zygomycetes are responsible for causing rhino-orbital mucormycosis which usually affects diabetic or immunocompromised patients. Infections of the nasal mucosa and paranasal sinuses occur in Stage I of ROCM, orbital involvement occurs in Stage II, and brain involvement occurs in Stage III, which mostly affects individuals with immunological or metabolic problems. Face discomfort and paraesthesia, headaches, enlarged orbits and nostrils, inflammation, drooping eyelids, proptosis, external and internal ophthalmoplegia, vision loss, and blackish necrosis of the palate and nasal mucosa are all symptoms of rhino-orbito-cerebral mucormycosis. Here we report a case of Rhino orbital cerebral mucormycosis in a 49-year-old male presented to an otorhinolaryngology department with at least 10 days of retro-orbital pain and headache for, bilateral nasal obstruction, right sided facial pain and swelling and drooping of right eyelids and loss of vision in right eye from 5 days. The patient was diagnosed with invasive fungal sinusitis and underwent skull base surgery a week before admission for liposomal amphotericin-B infusion. The patient had medical history of type II diabetes mellitus and hypertension for 8 years, acute ischemic stroke recently. The patient had a history of COVID-19 and was hospitalised for 25 days. The standard treatment for mucormycosis was initiated with Liposomal Amphotericin B (50 mg) Intravenous infusion-5 doses were given along with nasal packing every alternate day. Total cumulative dose of Amphotericin B-1500 mg was given. Early treatment and prompt treatment with Amphotericin B is necessary for avoiding devastating consequences. Keywords: Omega-3 Fatty Acids, Neuro Degenerative Disorder, Docosahexaenoic Acid, Elcosapentaenoic Acid.

Authors

Publication Details

Journal
Indian Journal of Pharmacy Practice
Published
2025-10-01
DOI
https://doi.org/10.5530/ijopp.20260258
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rhino-Orbital Cerebral Mucormycosis (ROCM): Effective Management with Liposomal Amphotericin B

Dr.Bhanushree R Dr.Bhanushree R, Ganesh P. Surahonne, Yogeesha Yogeesha BS
Indian Journal of Pharmacy Practice
Antifungal resistance and susceptibility
article

Rhino-Orbital Cerebral Mucormycosis (ROCM): Effective Management with Liposomal Amphotericin B

Dr.Bhanushree R Dr.Bhanushree R, Ganesh P. Surahonne, Yogeesha Yogeesha BS
article en

Abstract

Published on: September 2025 Indian Journal of Pharmacy Practice, 2026; 19(1):123-126. Case Report| doi: 10.5530/ijopp.20260258Authors and affiliation (s): Dhanush R1,*, Yogeesha BS2, Ganesh P Surahonne2 1Department of Pharmacy Practice, Bapuji Pharmacy College, Davangere, Karnataka, INDIA. 2Department of Otorhinolaryngology, SSIMS&RC, Davangere, Karnataka, INDIA. ABSTRACT Rhino-Orbital Cerebral Mucormycosis (ROCM) is a serious and often life-threatening fungal infection. The fungi class called zygomycetes are responsible for causing rhino-orbital mucormycosis which usually affects diabetic or immunocompromised patients. Infections of the nasal mucosa and paranasal sinuses occur in Stage I of ROCM, orbital involvement occurs in Stage II, and brain involvement occurs in Stage III, which mostly affects individuals with immunological or metabolic problems. Face discomfort and paraesthesia, headaches, enlarged orbits and nostrils, inflammation, drooping eyelids, proptosis, external and internal ophthalmoplegia, vision loss, and blackish necrosis of the palate and nasal mucosa are all symptoms of rhino-orbito-cerebral mucormycosis. Here we report a case of Rhino orbital cerebral mucormycosis in a 49-year-old male presented to an otorhinolaryngology department with at least 10 days of retro-orbital pain and headache for, bilateral nasal obstruction, right sided facial pain and swelling and drooping of right eyelids and loss of vision in right eye from 5 days. The patient was diagnosed with invasive fungal sinusitis and underwent skull base surgery a week before admission for liposomal amphotericin-B infusion. The patient had medical history of type II diabetes mellitus and hypertension for 8 years, acute ischemic stroke recently. The patient had a history of COVID-19 and was hospitalised for 25 days. The standard treatment for mucormycosis was initiated with Liposomal Amphotericin B (50 mg) Intravenous infusion-5 doses were given along with nasal packing every alternate day. Total cumulative dose of Amphotericin B-1500 mg was given. Early treatment and prompt treatment with Amphotericin B is necessary for avoiding devastating consequences. Keywords: Omega-3 Fatty Acids, Neuro Degenerative Disorder, Docosahexaenoic Acid, Elcosapentaenoic Acid.

Indian Journal of Pharmacy PracticeVol. 19(1)
Openalex Percentile: Top 67%
Antifungal resistance and susceptibility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Rhino-Orbital Cerebral Mucormycosis (ROCM): Effective Management with Liposomal Amphotericin B — Dr.Bhanushree R Dr.Bhanushree R, Ganesh P. Surahonne, et al. · Indian Journal of Pharmacy Practice (2025) | TGRS Research Map | TGRS